Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
University of Chicago
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Universitätsklinikum Hamburg-Eppendorf
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Institute of Hematology & Blood Diseases Hospital, China
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
University Hospital Schleswig-Holstein
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
St. Jude Children's Research Hospital
Case Comprehensive Cancer Center
Prince of Wales Hospital, Shatin, Hong Kong
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Sun Yat-sen University
Stanford University
Alliance for Clinical Trials in Oncology
Barbara Ann Karmanos Cancer Institute
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Associazione Italiana Ematologia Oncologia Pediatrica
Rutgers, The State University of New Jersey
Rutgers, The State University of New Jersey
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University Hospital Schleswig-Holstein